TY - JOUR
T1 - Antihypertensive effect of amaranth hydrolysate is comparable to the effect of low-intensity physical activity
AU - Cabrera-Chávez, Francisco
AU - Lopez-Teros, Veronica
AU - Gutiérrez-Arzapalo, Perla Yareli
AU - Cárdenas-Torres, Feliznando Isidro
AU - Rios-Burgueño, Efren Rafael
AU - Astiazaran-Garcia, Humberto
AU - Murúa, José Aldo Hernández
AU - González-Ochoa, Guadalupe
AU - Ramírez-Torres, Giovanni Isaí
AU - Ontiveros, Noé
N1 - Publisher Copyright:
© 2020 by the authors.
PY - 2020/8
Y1 - 2020/8
N2 - Background and objectives: Both antihypertensive peptide intake and physical activity help to control blood pressure. Our aim was to evaluate the impact of consuming amaranth antihypertensive peptides on systolic blood pressure (SBP) in normotensive rats and the magnitude and relevance of the peptide-induced antihypertensive effect in spontaneously hypertensive rats (SHR). Materials and Methods: Treatments (alcalase-generated amaranth protein hydrolysate, captopril, or water) were given by gavage and the SBP measured by the tail-cuff method. Physical activity was performed five days/week (for twenty weeks). Results: The normotensive rats' SBP (mmHg, average/group) remained unaffected after amaranth antihypertensive peptide supplementation (121.8) (p > 0.05 vs controls). In SHR, the SBP was lowered by 24.6 (sedentary/supplemented at two weeks), 42.0 (sedentary/supplemented at eight weeks), and 31.5 (exercised/non-supplemented at eight weeks) (p < 0.05 vs sedentary/non-supplemented). The combination of supplementation and physical activity lowered the SBP by 36.2 and 42.7 (supplemented/exercised at two weeks and eight weeks, respectively) (p<0.05 vs sedentary/non-supplemented), but it did not have additional antihypertensive benefits (p > 0.05 vs sedentary/supplemented at eight weeks or exercised/non-supplemented at eight weeks). Conclusions: Amaranth antihypertensive peptide supplementation has no impact on SBP in normotensive rats. This supplementation develops sustained antihypertensive benefits in SHR, which are similar to the antihypertensive effect developed after eight-or twenty-week low-intensity physical activity. These findings have implications for developing safe and effective peptide-based functional foods.
AB - Background and objectives: Both antihypertensive peptide intake and physical activity help to control blood pressure. Our aim was to evaluate the impact of consuming amaranth antihypertensive peptides on systolic blood pressure (SBP) in normotensive rats and the magnitude and relevance of the peptide-induced antihypertensive effect in spontaneously hypertensive rats (SHR). Materials and Methods: Treatments (alcalase-generated amaranth protein hydrolysate, captopril, or water) were given by gavage and the SBP measured by the tail-cuff method. Physical activity was performed five days/week (for twenty weeks). Results: The normotensive rats' SBP (mmHg, average/group) remained unaffected after amaranth antihypertensive peptide supplementation (121.8) (p > 0.05 vs controls). In SHR, the SBP was lowered by 24.6 (sedentary/supplemented at two weeks), 42.0 (sedentary/supplemented at eight weeks), and 31.5 (exercised/non-supplemented at eight weeks) (p < 0.05 vs sedentary/non-supplemented). The combination of supplementation and physical activity lowered the SBP by 36.2 and 42.7 (supplemented/exercised at two weeks and eight weeks, respectively) (p<0.05 vs sedentary/non-supplemented), but it did not have additional antihypertensive benefits (p > 0.05 vs sedentary/supplemented at eight weeks or exercised/non-supplemented at eight weeks). Conclusions: Amaranth antihypertensive peptide supplementation has no impact on SBP in normotensive rats. This supplementation develops sustained antihypertensive benefits in SHR, which are similar to the antihypertensive effect developed after eight-or twenty-week low-intensity physical activity. These findings have implications for developing safe and effective peptide-based functional foods.
KW - ACE-1
KW - Amaranth hydrolysate
KW - Hydrolysis
KW - Physical activity
UR - http://www.scopus.com/inward/record.url?scp=85089800654&partnerID=8YFLogxK
U2 - 10.3390/app10165706
DO - 10.3390/app10165706
M3 - Artículo
AN - SCOPUS:85089800654
SN - 2076-3417
VL - 10
JO - Applied Sciences (Switzerland)
JF - Applied Sciences (Switzerland)
IS - 16
M1 - 5706
ER -